About us Contacts Drug interactions: 390 212
Drug search by name

Dabigatran and Tolvaptan (Jynarque/Jinarc)

Determining the interaction of Dabigatran and Tolvaptan (Jynarque/Jinarc) and the possibility of their joint administration.

Check result:
Dabigatran <> Tolvaptan (Jynarque/Jinarc)
Relevance: 22.08.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Tolvaptan may increase the blood levels and effects of dabigatran. Combining these medications may increase the risk of bleeding complications. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Call your doctor promptly if you experience paleness of skin, fatigue, dizziness, fainting, unusual bleeding or bruising, swelling, vomiting, blood in your urine or stools, headache, or weakness during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with inhibitors of P-glycoprotein (P-gp) such as tolvaptan may increase the plasma concentration of dabigatran etexilate, a substrate of the efflux transporter. When digoxin, a P-gp probe substrate, was administered with multiple doses of tolvaptan (60 mg once a day), digoxin AUC and Cmax increased by 20% and 30%, respectively.

MANAGEMENT: Product labeling advises that use of dabigatran with P-gp inhibitors in patients with severe renal impairment (CrCl less than 30 mL/min) should be avoided. In patients taking dabigatran for the treatment or prophylaxis of deep venous thrombosis (DVT) or pulmonary embolism (PE), use of dabigatran with P-gp inhibitors in moderate renal impairment (CrCl 30 to 50 mL/min) should be avoided.

References
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Cerner Multum, Inc. "Australian Product Information." O 0
  • "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim, Ridgefield, CT.
  • "Product Information. Samsca (tolvaptan)." Otsuka American Pharmaceuticals Inc, Rockville, MD.
Dabigatran

Generic Name: dabigatran

Brand name: Pradaxa

Synonyms: Dabigatran Etexilate

Tolvaptan (Jynarque/Jinarc)

Generic Name: tolvaptan

Brand name: Samsca, Jynarque

Synonyms: Tolvaptan

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle